COVID-19 Therapeutic Drug Development

Various research strategies are being deployed to control the COVID-19 pandemic, including a search for a vaccine. This feed covers primarily the ongoing research efforts that are focused on repurposing existing antiviral drugs and finding novel therapeutic treatments.

January 16, 2022

The Inhibition of RNA Viruses by Amaryllidaceae Alkaloids: Opportunities for the Development of Broad-Spectrum Anti-Coronavirus Drugs.

Chemistry, an Asian Journal
Shen TanLorenzo V White
January 15, 2022
Open Access

COVID MED - An Early Pandemic Trial of Losartan for Hospitalized COVID-19 Patients

MedRxiv : the Preprint Server for Health Sciences
Daniel FreilichA. Gadomski
January 15, 2022

Covid-19: WHO recommends baricitinib and sotrovimab to treat patients.

BMJ : British Medical Journal
Zosia Kmietowicz
January 15, 2022
Case Report

Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19.

Clinical Nephrology. Case Studies
Mansour MbengueAbdou Niang
January 15, 2022

Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.

Frontiers in Chemistry
Marko JukičUrban Bren
January 15, 2022

DeepMGT-DTI: Transformer network incorporating multilayer graph information for Drug-Target interaction prediction.

Computers in Biology and Medicine
Peiliang ZhangBo Jin
January 14, 2022
Open Access

High-cited favorable studies for COVID-19 treatments ineffective in large trials

MedRxiv : the Preprint Server for Health Sciences
John P.A. Ioannidis
January 14, 2022
Open Access

Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients - A Systematic Review

MedRxiv : the Preprint Server for Health Sciences
Daniel FreilichA. Gadomski
January 14, 2022
Open Access

Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort.

PloS One
Katie BechmanSam Norton
January 14, 2022

COVID-19 with Baricitinib-Induced Symptomatic Creatinine Kinase Elevation Article.

QJM : Monthly Journal of the Association of Physicians
Y SaishojiH Yura
January 14, 2022

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicenter, placebo-controlled trial clinical trial.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Mohammad BosaeedAhmed Alaskar
January 14, 2022

Low- Versus High-Dose Methylprednisolone in Adult Patients With Coronavirus Disease 2019: Less Is More.

Open Forum Infectious Diseases
Seema JoshiMayur Ramesh
January 14, 2022

QTc prolongation in patients with COVID-19: a retrospective chart review.

Translational and Clinical Pharmacology
Suphannika Prateepjarassaeng PornwattanakaveeNattawut Leelakanok
January 14, 2022

Polysaccharides to combat viruses (Covid-19) and microbes: New updates.

Current Molecular Pharmacology
Manaf AlMatarFatih Köksal
January 14, 2022

Aptamers Against COVID-19: An Untested Opportunity.

Mini Reviews in Medicinal Chemistry
Annekathrin Haberland, Johannes Müller
January 14, 2022

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis - the special case of molnupiravir.

Environmental and Molecular Mutagenesis
Michael D WatersFengyu Zhang
January 14, 2022

Subacute thyroiditis during the COVID-19 pandemic: a prospective study.

Journal of Endocrinological Investigation
A B BahçecioğluM F Erdoğan
January 14, 2022

Self medication practices and its determinants in health care professionals during the coronavirus disease-2019 pandemic: cross-sectional study.

International Journal of Clinical Pharmacy
Ogochukwu Chinedum OkoyeJohn Oghenevwirhe Ohaju-Obodo

Sign up to follow this feed and discover related papers.

Related Feeds

AI-driven COVID-19 Management

Artificial intelligence (AI) offers a powerful new tool that could potentially be instrumental in controling and managing the SARS-CoV-2 virus. The papers in this feed report on the applications of AI to the current pandemic, which may be able to predict the location of the next outbreak, or facilitate new drug design.


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

COVID-19 Cardiovascular Complications

Growing evidence shows that COVID-19 can result in serious complications affecting the cardiovascular system, including dysrhythmias, myocarditis, acute myocardial infarction, and heart failure. This feed follows studies investigating the effects of SARS-CoV-2 infection on the heart.

COVID-19 Clinical Diagnosis

COVID-19 patients typically present with high fever and a persistent cough. This feed focuses on clinical diagnosis, including RT-PCR testing for the presence of SARS-CoV-2 and radiographic assessment of lungs.

COVID-19 Clinical Management

While most COVID-19 infections cause only mild to moderate symptoms, severely affected patients, such as those presenting with pneumonia, ARDS or septic shock, require hospitalization. This feed focuses on clinical management of patients using oxygen therapy, ventilation, and other treatment strategies, and covers some medical case reports.

COVID-19 Comorbidities

COVID-19 represents a particular challenge to people with serious chronic medical conditions such as diabetes, hypertension, cardiovascular disease, and chronic lung disease. Research into the intersection between comorbidities and COVID-19 is focusing on risks and treatment outcomes for these patients.

COVID-19 Complications

A growing number of complications associated with COVID-19 has been identified. This feed focuses primarily on cardiovascular and respiratory manifestations in severely ill patients.

COVID-19 Covalescent Plasma Therapy

Convalescent plasma therapy, where passive polyclonal antibody obtained from recovered patients are used to provide immediate immunity, has been tested in respiratory infections such as the 2009-2010 H1N1 influenza virus pandemic and the 2003 SARS-CoV-1 epidemic. This feed follows ongoing research efforts and clinical trials exploring covalescent plasma therapy as a potential treatment strategy for COVID-19.

COVID-19 Epidemiology and Demography

Epidemiological studies play a crucial role in understanding and managing the progression of COVID-19. Research followed in this feed includes studies of transmission dynamics and the change of the basic reproductive number (R) as new pubic health measures take effect.

COVID-19 Immune Response

Understanding the innate and acquired immune response to SARS-CoV-2 is essential for development of COVID-19 therapeutic treatment and design of prophylactic vaccines. This feed surfaces immunological studies, including studies into the cytokine storm that has been observed in severely ill patients.

© 2022 Meta ULC. All rights reserved